GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RBC Bioscience Corp (ROCO:6848) » Definitions » Capex-to-Operating-Cash-Flow

RBC Bioscience (ROCO:6848) Capex-to-Operating-Cash-Flow : 0.21 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is RBC Bioscience Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

RBC Bioscience's Capital Expenditure for the six months ended in Dec. 2023 was NT$-4.11 Mil. Its Cash Flow from Operations for the six months ended in Dec. 2023 was NT$19.37 Mil.

Hence, RBC Bioscience's Capex-to-Operating-Cash-Flow for the six months ended in Dec. 2023 was 0.21.


RBC Bioscience Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for RBC Bioscience's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RBC Bioscience Capex-to-Operating-Cash-Flow Chart

RBC Bioscience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial 0.24 0.58 - 1.52 0.49

RBC Bioscience Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 0.91 - - 0.21

Competitive Comparison of RBC Bioscience's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, RBC Bioscience's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RBC Bioscience's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RBC Bioscience's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where RBC Bioscience's Capex-to-Operating-Cash-Flow falls into.



RBC Bioscience Capex-to-Operating-Cash-Flow Calculation

RBC Bioscience's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-6.464) / 13.208
=0.49

RBC Bioscience's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-4.114) / 19.374
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RBC Bioscience  (ROCO:6848) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


RBC Bioscience Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of RBC Bioscience's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


RBC Bioscience (ROCO:6848) Business Description

Traded in Other Exchanges
N/A
Address
Lane 235, Baoqiao Road, 3rd Floor, No. 132, New Taipei City, TWN, 23145
RBC Bioscience Corp is a bio sciences company. Its products include Real Genomics, MagCore Automated Nucleic Acid Extractor, and MagCore Nucleic Acid Extraction KIT.

RBC Bioscience (ROCO:6848) Headlines

No Headlines